Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma

doi:10.21037/atm.2020.02.142

	Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma
	Huang, Minran 1,2,3,7; Jin, Jiaoyue 1,2,7; Zhang, Fanrong 2,5,6; Wu, Yingxue 1,2,7; Xu, Chenyang 1,2,7; Ying, Lisha 2,4; Su, Dan 1,2,7
刊名	ANNALS OF TRANSLATIONAL MEDICINE
	2020-03-01
卷号	8
关键词	Esophageal squamous cell carcinoma (ESCC) TP53 mutation next-generation sequencing (NGS) prognosis
ISSN号	2305-5839
DOI	10.21037/atm.2020.02.142
通讯作者	Su, Dan(sudan@zjcc.org.cn)
英文摘要	Background: TP53 is frequently altered in esophageal squamous cell carcinoma (ESCC). However, the landscape of TP53 mutation and its effects on patients remain controversial. Methods: Somatic mutations of TP53 in 161 patients with resectable ESCC were identified by next-generation sequencing (NGS) and verified by immunohistochemistry (IHC). Patients were stratified into seven TP53 mutations, and depending on the extent of the effect on the encoded protein, it was divided into "disruptive" and "non-disruptive" types. The association of TP53 mutation with clinicopathological properties and disease outcome was investigated. Results: TP53 mutations were discovered in 85.7% patients, of which 68.9% carried mutations in the DNA-binding domain (DBD). A total of 47.8% and 37.9% patients had disruptive and non-disruptive TP53 mutations, respectively. Most patients carried only one TP53 mutation, but 15.5% had double mutations. TP53 mutations were dominant in exons 5 to 8. Missense mutation was the most frequent (97/163, 59.5%), and the top five frequently occurring variations included R273X, Y220X, H193, H179X, and R175H. Multivariable analysis revealed non-disruptive mutation in TP53 DBD as the independent prognostic predictor for progression-free survival (PFS) and overall survival (OS). The expression of p53 positively correlated with non-disruptive mutation in DBD. Patients with high p53 protein expression showed better outcomes. Conclusions: Non-disruptive mutation in TP53 DBD serves as an independent beneficial prognostic factor of prolonged survival in resectable ESCC.
资助项目	National Natural Science Foundation of China[81472203] ; Major Science and Technology Plan of Zhejiang Medicine and Health - National Health Commission[WKJ-ZJ-1902]
WOS关键词	GENE COPY NUMBER ; GAIN-OF-FUNCTION ; MUTANT P53 ; PROTEIN EXPRESSION ; MISSENSE MUTATIONS ; HUMAN CANCER ; SURVIVAL ; PREDICTION ; HEAD ; EGFR
WOS研究方向	Oncology ; Research & Experimental Medicine
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000522784900059
资助机构	National Natural Science Foundation of China ; Major Science and Technology Plan of Zhejiang Medicine and Health - National Health Commission
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/103469]
专题	中国科学院合肥物质科学研究院
通讯作者	Su, Dan
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Dept Pathol, Hangzhou 310022, Peoples R China 2.Chinese Acad Sci, ICBM, Hangzhou, Peoples R China 3.Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Oncol, Hangzhou 310053, Peoples R China 4.Univ Chinese Acad Sci, Canc Hosp, Hangzhou 310022, Peoples R China 5.Zhejiang Canc Hosp, Dept Breast Surg, Hangzhou 310022, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Dept Breast Surg, Hangzhou 310022, Peoples R China 7.Zhejiang Canc Hosp, Dept Pathol, Hangzhou 310022, Peoples R China
推荐引用方式 GB/T 7714	Huang, Minran,Jin, Jiaoyue,Zhang, Fanrong,et al. Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma[J]. ANNALS OF TRANSLATIONAL MEDICINE,2020,8.
APA	Huang, Minran.,Jin, Jiaoyue.,Zhang, Fanrong.,Wu, Yingxue.,Xu, Chenyang.,...&Su, Dan.(2020).Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma.ANNALS OF TRANSLATIONAL MEDICINE,8.
MLA	Huang, Minran,et al."Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma".ANNALS OF TRANSLATIONAL MEDICINE 8(2020).